Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,221.42 -1.26 (-0.02%) Dow
39,431.51 -81.33 (-0.21%) Nasdaq
16,388.24 +47.37 (+0.29%) Bitcoin USD
63,099.63 +1,772.93 (+2.89%) CMC Crypto 200
1,297.06 +36.86 (+2.92%)
NVO Jan 2026 92.500 call
| Previous close | 43.41 |
| Open | 44.95 |
| Bid | 49.50 |
| Ask | 52.30 |
| Strike | 92.50 |
| Expiry date | 2026-01-16 |
| Day's range | 43.41 - 44.95 |
| Contract range | N/A |
| Volume | |
| Open interest | 127 |
BenzingaNovo Nordisk's Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing Frequency
Monday, Novo Nordisk A/S (NYSE:NVO) released headline results from the FRONTIER 2 Phase 3a trial of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in hemophilia A patients 12 years or older with or without inhibitors. Read Next: Weight Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro. The trial achieved its co-primary endpoints by demonstrating a statistically significant a
GlobeNewswireNovo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in people aged 12 years or older with haemophilia A with or without inhibitors. The trial achieved its co-primary endp
